United Therapeutics (UTHR) Misses Q2 EPS, Revenues Beat
Tweet
Share
E-mail
Get Alerts UTHR Hot Sheet
Price: $545.96 +0.10%
Revenue Growth %: +1.5%
Financial Fact:
Cost of product sales: 23.6M
Today's EPS Names:
PLCE, COE, JVA, More
Revenue Growth %: +1.5%
Financial Fact:
Cost of product sales: 23.6M
Today's EPS Names:
PLCE, COE, JVA, More
Join SI Premium – FREE
United Therapeutics (NASDAQ: UTHR) reported Q2 EPS of $2.41, $1.97 worse than the analyst estimate of $4.38. Revenue for the quarter came in at $466.9 million versus the consensus estimate of $460.67 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- Dollarama Inc. (DOL:CN) (DLMAF) PT Raised to Cdn$221 at BMO Capital
- UBS Reiterates Neutral Rating on Clorox (CLX) as External Challenges Persist
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
